Srivastava Alok

Primaquine phosphate, 8-[(4-amino-1-methyl butyl)amino]-6-metoxyquinoline phosphate, a synthetic compound with potent antimalarial activity and clinical use for treatment of relapses of Plasmodium vivax infections. The drug is usually oral administered for 7-14 consecutive days to achieve radical cure and is known to produce adverse side-effect including gastrointestinal distress, nausea and methaemoglobinemia with cyanosis.  In transdermal drug delivery system provide benefits over the oral administration. It is an alternative drug delivery system, in recent years, high patient acceptance in many clinical conditions and the advantages of delivering drugs across the skin for systemic circulation.  Fabrication and Evaluation of matrix type Transdermal Patches of Primaquine Phosphate with different ratio of eudragit-L100 and S-100 combination by the solvent evaporation technique. All the patches have been evaluated for their Physiochemical properties was studied by infrared Spectroscopy. Formulation F1 was found best among the all formulation. Hence F1 formulation was used to incorporate penetration enhancer labrafac™ PD, labrefil® 1944CS and lauroglucol™ FCC. By using this three penetration enhancer nine formulation L1 to L9 was fabricated to increasing volume of 0.5ml, 1.0ml, 1.5 ml. All the formulation was tested for thickness, weight variation, folding endurance, surface pH, moisture content and %drug content. L6 was showing maximum drug content and folding endurance. The in-vitro release study was carried out with Shimadzu HPLC system. L6 formulation showed the best release.